{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:54Z","timestamp":1793779254051,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7202216"],"award-info":[{"award-number":["7202216"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970698"],"award-info":[{"award-number":["81970698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970708"],"award-info":[{"award-number":["81970708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and<jats:italic>Clinicaltrial.gov<\/jats:italic>were searched from the inception to November 2020. Randomized controlled trials of SGLT2i conducted in population containing diabetic patients with reports of amputation, peripheral arterial disease (PAD) and diabetic foot (DF) events were included. Random-effect model, fixed-effect model and meta-regression analysis were accordingly used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,925\/33,414, 36,446\/28,685 and 31,907\/25,570 respectively. Compared with non-SGLT2i users, the risks of amputation and PAD were slightly increased in patients with canagliflozin treatment (amputation: OR\u2009=\u20091.60, 95% CI 1.04 to 2.46; PAD: OR\u2009=\u20091.53, 95\u00a0% CI 1.14 to 2.05). Meta-regression analyses indicated that greater weight reduction in SGLT2i users was significantly associated with the increased risks of amputation (\u03b2 = \u2212 0.461, 95% CI \u2212 0.726 to \u2212\u00a00.197), PAD (\u03b2 = \u2212\u00a00.359, 95% CI \u2212\u00a00.545 to \u2212\u00a00.172) and DF (\u03b2 = \u2212\u00a00.476, 95% CI \u2212\u00a00.836 to \u2212\u00a00.116). Lower baseline diastolic blood pressure (\u03b2 = \u2212\u00a00.528, 95% CI \u2212\u00a00.852 to \u2212\u00a00.205), more systolic blood pressure reduction (\u03b2 = \u2212\u00a00.207, 95% CI \u2212\u00a00.390 to \u2212\u00a00.023) and more diastolic blood pressure reduction (\u03b2 = \u2212\u00a00.312, 95% CI \u2212\u00a00.610 to \u2212\u00a00.015) were significantly associated with the increased risks of amputation, PAD and DF respectively in patients with SGLT2i treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The risks of amputation and PAD were slightly increased in patients with canagliflozin treatment. Reductions in body weight and blood pressure were associated with lower limb complications in patients with SGLT2i treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-021-01276-9","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T17:03:59Z","timestamp":1619629439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["SGLT2 inhibitors and lower limb complications: an updated meta\u2010analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Chu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"1","key":"1276_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","volume":"18","author":"AY Kluger","year":"2019","unstructured":"Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1276_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"key":"1276_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","volume":"14","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol. 2018;14:326\u201328.","journal-title":"Nat Rev Endocrinol"},{"key":"1276_CR4","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine."},{"key":"1276_CR5","doi-asserted-by":"publisher","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","volume":"163","author":"S Miyashita","year":"2020","unstructured":"Miyashita S, Kuno T, Takagi H, Sugiyama T, Ando T, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Kanei Y, Bangalore S. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials. Diabetes Res Clin Pract. 2020;163:108136.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"1276_CR6","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0234065.","journal-title":"PLoS ONE"},{"key":"1276_CR7","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","volume":"370","author":"M Fralick","year":"2020","unstructured":"Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812.","journal-title":"BMJ"},{"issue":"5","key":"1276_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1276_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pds.932","volume":"13","author":"JA Erkens","year":"2004","unstructured":"Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Antihypertensive Drug Therapy and the Risk of Lower Extremity Amputations in Pharmacologically Treated Type 2 Diabetes Patients. Pharmaco epidemiol Drug Saf. 2004;13(3):139\u201346.","journal-title":"Pharmaco epidemiol Drug Saf"},{"issue":"1","key":"1276_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-017-0611-x","volume":"16","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Node K. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc Diabetol. 2017;16(1):129.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1276_CR11","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2169\/internalmedicine.55.6367","volume":"55","author":"S Hirose","year":"2016","unstructured":"Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y. Impact of the 8-week Administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2 diabetes mellitus. Intern Med. 2016;55(22):3239\u201345.","journal-title":"Intern Med"},{"issue":"7","key":"1276_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.14740\/jocmr3038w","volume":"9","author":"T Kawata","year":"2017","unstructured":"Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res. 2017;9(7):586\u201395.","journal-title":"J Clin Med Res"},{"issue":"3","key":"1276_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355\u201364.","journal-title":"Diabetes Care"},{"issue":"2","key":"1276_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest"},{"issue":"1","key":"1276_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2013","unstructured":"Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1276_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819\u201337.","journal-title":"Cell Metab"},{"issue":"4","key":"1276_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/jdi.12625","volume":"8","author":"X Cai","year":"2017","unstructured":"Cai X, Ji L, Chen Y, Yang W, Zhou L, Han X, Zhang S, Ji L. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig. 2017;8(4):510\u20137.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1276_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","volume":"44","author":"E Patorno","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, Kim DH, Dave C, Glynn RJ, Munshi MN, Schneeweiss S, Wexler DJ, Kim SC. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44(3):826\u201335.","journal-title":"Diabetes Care"},{"key":"1276_CR19","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, Eliasson B, Svensson AM, Franz\u00e9n S, Gudbj\u00f6rnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"issue":"7","key":"1276_CR20","doi-asserted-by":"crossref","first-page":"e015323","DOI":"10.1161\/JAHA.119.015323","volume":"9","author":"M Hu","year":"2020","unstructured":"Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide\u20101 receptor agonist and sodium\u2010glucose cotransporter\u20102 inhibitor treatment in type 2 diabetes mellitus: a meta\u2010analysis. J Am Heart Assoc. 2020;9(7):e015323.","journal-title":"J Am Heart Assoc"},{"key":"1276_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","volume":"135","author":"I Horie","year":"2018","unstructured":"Horie I, Abiru N, Hongo R, Nakamura T, Ito A, Haraguchi A, Natsuda S, Sagara I, Ando T, Kawakami A. Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment. Diabetes Res Clin Pract. 2018;135:178\u201384.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1276_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1507\/endocrj.EJ19-0013","volume":"66","author":"R Kosugi","year":"2019","unstructured":"Kosugi R, Nakatani E, Okamoto K, Aoshima S, Arai H, Inoue T. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients. Endocr J. 2019;66(8):677\u201382.","journal-title":"Endocr J"},{"issue":"1","key":"1276_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y. Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter-associated incorporation accounting for its pharmacodynamic and pharmacokinetic features. J Pharmacol Exp Ther. 2016;358(1):94\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"1276_CR24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/dme.13645","volume":"35","author":"H Sims","year":"2018","unstructured":"Sims H, Smith KH, Bramlage P, Minguet J, Sotagliflozin. A dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus. Diabet Med. 2018;35(8):1037\u201348.","journal-title":"Diabet Med"},{"issue":"1","key":"1276_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-020-0990-2","volume":"19","author":"SC Shao","year":"2020","unstructured":"Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol. 2020;19(1):17.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1276_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311.","journal-title":"Diabetes Care"},{"issue":"4","key":"1276_CR27","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.diabet.2021.101224","volume":"47","author":"V Spallone","year":"2021","unstructured":"Spallone V, Valensi P. SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement. Diabetes Metab. 2021;47(4):101224.","journal-title":"Diabetes Metab"},{"issue":"1","key":"1276_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G, Solini A, Bonadonna RC, Dei Cas A. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol. 2020;19(1):46.","journal-title":"Cardiovasc Diabetol"},{"issue":"S1","key":"1276_CR29","first-page":"111-24","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(S1):111\u201324.","journal-title":"Diabetes Care"},{"issue":"1","key":"1276_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","volume":"19","author":"HF Lee","year":"2020","unstructured":"Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovasc Diabetol. 2020;19(1):160.","journal-title":"Cardiovasc Diabetol"}],"updated-by":[{"DOI":"10.1186\/s12933-021-01306-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01276-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T22:22:48Z","timestamp":1698963768000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01276-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01276-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12933-021-01306-6","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-021-01306-6","URL":"https:\/\/doi.org\/10.1186\/s12933-021-01306-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publicaton"}},{"value":"LJ has received fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly, Roche, Sanofi-Aventis and Takeda. All authors have completed the ICMJE uniform disclosure form at(available on request from the corresponding author) and declare. No other support from any organization for the submitted work other than that described above.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}